தே தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தே தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தே தகவல்தொடர்புகள் Today - Breaking & Trending Today

Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps


Nachricht vom 23.07.2021 | 07:00
Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps
DGAP-News: BB BIOTECH AG
/ Key word(s): Half Year Report/Interim Report
23.07.2021 / 07:00
Media release of July 23, 2021
Interim report of BB Biotech AG as at June 30, 2021
Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps
Inflation moved higher during the second quarter as the economic recovery gathered steam, triggering temporary outflows of investor capital from growth sectors. Central banks signaled that the rise in inflation would be short-lived, after which capital began to flow back into tech and healthcare stocks. BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021. Their total return for the first half of 2021 including the dividend payout was 22.2% in CHF and 21.3% in EUR. BB Biotech took profi ....

Tanja Chicherio , Claude Mikkelsen , Susan Galbraith , Esperion Nexlizet Nexletol , Silvia Schanz , Thomas Egger , Neurocrine Ingrezza , Essa Pharma , Radiu Tymlos , Maria Grazia Iten Alderuccio , Office Of The Inspector General , Ute Communications , Us Federal Trade Commission , Dow Jones , Oncology Research Development , Fate Therapeutics , Revolution Medicines , Relay Therapeutics , Nasdaq Composite Index , Some European , Healthcare Index , Nasdaq Biotech Index , Net Asset Value , Oncology Research , Annual General , Trade Commission ,

Investegate |BB BIOTECH AG Announcements | BB BIOTECH AG: Vaccines leading the way out of the pandemic


DGAP-News: BB BIOTECH AG
/ Key word(s): Annual Results/Dividend
BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed
22.01.2021 / 07:00
Media release as of January 22, 2021
Portfolio of BB Biotech AG as of December 31, 2020
Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed
BB Biotech performed well in 2020 in a volatile market environment. The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies. M&A activity picked up substantially in H2 2020, further driving solid performance as the year came to a close. The fourth quarter alone drove a portfolio gain of 20.6% in CHF, 20.4% in EUR and 25.5% in USD for BB Biotech - reflecting a net gain of CHF 665 mn. In parallel, the share price appreciated by 10.9% in CHF and 9.0% in EUR. BB Biotech exited four holdings and added ....

United States , White House , District Of Columbia , Neurocrine Biosciences , Jeffreyd Zients , Tanja Chicherio , Claude Mikkelsen , Bristol Myers Squibb , Silvia Siegfried Schanz , Xavier Becerra , Thomas Egger , Maria Grazia Iten Alderuccio , Investment Management Team Of Bellevue Asset , Scholar Rock Holding , Alnylam Pharmaceuticals , Generation Bio Co , Kezar Life Sciences , Radius Health , Dow Jones , Obama National Economic Council , Vertex Pharmaceuticals , Alexion Pharmaceuticals , Ute Communications , Nektar Therapeutics , Agios Pharmaceuticals , Myovant Sciences ,